Abstract: A magnesium alloy having high strength and high ductility and in which at least one of corrosion resistance and flame resistance is enhanced, or a method of manufacturing the same. The magnesium alloy contains an atomic % of Ca and b atomic % of Al, totally contains k atomic % of at least one element selected from a group consisting of Mn, Zr, Ag, Y and Nd, has a composition in which a remaining part is formed of Mg and contains c volume % of (Mg, Al)2Ca, a, b, c and k satisfying formulae (1) to (4) and (21) below. The (Mg, Al)2Ca is dispersed and the at least one element is an element that enhances at least one of corrosion resistance and flame resistance: (1) 3?a?7, (2) 4.5?b?12, (3) 1.2?b/a?3.0, (4) 10?c?35, (21) 0<k?0.3.

Abstract: A method produces a composite of a polymer and tungstic acid and/or molybdic acid; and the composite obtained by the method has high transparency and a desired refractive index. This composite contains tungstic acid and/or molybdic acid and a polymer that has a number average molecular weight of 1,000-10,000,000 and an ether bond and/or an ester bond. The content of tungstic acid and/or molybdic acid in the composite is 0.01-95% by weight.

Abstract: Provided is a biodegradable polymer coating stent effective in delaying the damage of physical properties (particularly radial force) of a core structure. The stent includes a core structure of a bioabsorbable material (e.g., Mg), a first coating layer of a first polymer with biodegradability, and a second coating layer of a second polymer with biodegradability, wherein the first coating layer covers the whole surface of the core structure; the second coating layer covers a part or the whole surface of the first coating layer; the first polymer has a glass transition point of lower than 37° C.; and the second polymer has a glass transition point of 47° C. or higher.

Abstract: The purpose of the present invention is to provide a process or method that can be utilized when deriving a three-dimensional structure of a kidney from pluripotent stem cells such as ES cells or iPS cells. The differentiation inducing method is characterized by culturing pluripotent cells with the following three steps, in order: (a) a step of culturing an embryoid body induced from the pluripotent stem cells in medium containing Bmp4 and a high-concentration (concentration A) Wnt agonist; (b) a step of culturing the embryoid body in medium which contains activin, Bmp4, retinoic acid and a middle-concentration (concentration B) Wnt agonist; and (c) a step of culturing the embryoid body in medium containing Fgf9 and a low-concentration (concentration C) Wnt agonist (herein, the Wnt agonist concentrations is concentration A>concentration B>concentration C).

Abstract: Various embodiments relate to a compound of the formula (I): wherein X, X1, R1-R4 and R7 are defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I), or a pharmaceutical compositions comprising compounds of the formula (I), to a patient in need thereof.

Abstract: An object of the present invention is to provide a method of producing a myeloid blood cell possessing a proliferative capability. According to the present invention, provided is a method of producing a myeloid blood cell possessing a proliferative capability, including forcedly expressing (A) a cMYC gene, and (B) at least one gene selected from the group consisting of a BMI1 gene, an EZH2 gene, an MDM2 gene, an MDM4 gene, and an HIF1A gene in a myeloid blood cell.

Abstract: An electrolytic treatment method in which a predetermined treatment is performed using treatment subject ions contained in a treatment liquid, the method including: an electrode positioning step for positioning a direct electrode and a counter electrode so as to sandwich the treatment liquid, and positioning an indirect electrode for forming an electric field in the treatment liquid; a treatment subject ion migration step for applying a voltage to the indirect electrode and thereby moving the treatment subject ions in the treatment liquid to the counter electrode side; and a treatment subject ion redox step for applying a voltage between the direct electrode and the counter electrode and thereby oxidizing or reducing the treatment subject ions which have migrated to the counter electrode side.

Abstract: A method for producing a model animal which has a desired lifetime, and in which a predetermined biological reaction can be induced, and a model animal are provided. The present invention produces a first individual in which a gene of interest is heterozygously deficient using a first ES cell from a non-human mammalian animal. Meanwhile, a fragment containing a homologous gene that has homology to the gene of interest is made, a second ES cell constituted so that a predetermined region on X chromosome of the animal can be substituted is used, and the fragment is introduced into the second ES cell to generate a substituted ES cell in which the predetermined region has been substituted with the fragment. A second individual is produced using the substituted ES cell. The first individual and the second individual are mated with each other to produce a model animal.

Abstract: The purpose of the present invention is to provide a method and a culture medium which are capable of efficiently inducing the differentiation of pluripotent stem cells such as ES cells and iPS cells into desired cells by a simple means. The differentiation of pluripotent stem cells can be induced by culturing mammal-derived pluripotent stem cells in a differentiation culture medium that does not contain at least one amino acid selected from the group consisting of methionine, leucine, cysteine, tyrosine and arginine. Also provided is a differentiation-inducing culture medium which does not contain at least one amino acid selected from the group consisting of methionine, leucine, cysteine, tyrosine and arginine.

Abstract: Provided are a method for preparing a mammalian ovum or embryo in which zona pellucida has been thinned or eliminated, and a method for fertilization using the mammalian ovum prepared by the aforementioned method. The resulting mammalian ovum or embryo is capable of realizing an improved fertilization rate and development rate when used for in vitro fertilization, transplantation of a fertilized ovum, or for preparation of an embryo in the early stages of development used in the production of a genetically modified animal.

Abstract: An object of the invention is to provide a thin film manufacturing device which further reduces a load on a substrate. Provided is a thin film manufacturing device for forming a thin film on a substrate by supplying a mist of a solution including a thin-film forming material to the substrate, characterized in that the device includes: a plasma generation unit including a first electrode and a second electrode disposed closer to one surface of the substrate, which generates plasma between the first electrode and the second electrode; and a mist supply unit which passes the mist between the first electrode and the second electrode and supplies the mist to the substrate.

Abstract: An object of the present invention is to provide a pluripotent cell having high safety in application to regenerative medicine, and a method for production thereof. Another object of the present invention is to provide a pluripotent cell, particularly, having less concern for safety, such as a problem of cancerization of a cell, and the presence of bacteria in a cell, and a method for production thereof. According to the present invention, there is provided a method for producing a pluripotent cell from a somatic cell. The method comprises a step of inducing reprogramming of a somatic cell, by contacting the cell with a ribosome fraction derived from an organism. Further, according to the present invention, there is provided a composition for inducing reprogramming of a cell, comprising a ribosome fraction derived from an organism.

Abstract: An aluminium-based conductive material used in a driving part of robots or various devices and used, for example, in a wiring that is loaded with cyclic bending, as well as an electric wire and a cable using the same, contains 0.1 to 1.0 mass % of scandium and further contains, as a rest part, aluminium and unavoidable impure substances and is formed of a metal texture 10 having crystal grains 11 with an average grain size of 2 ?m or less and aluminium-scandium series nanoprecipitates generated in a grain boundary 12 of the crystal grains 11. Further, it is preferable that the metal texture 10 contains the crystal grains 11 of 1 ?m or less at a cross sectional ratio of 15% or more.

Abstract: The present invention provides a method for detection of an inflammatory reaction, which comprises using a transformant or transgenic non-human animal transfected with a vector comprising a promoter for a gene encoding an inflammatory cytokine, a gene encoding a reporter protein, a gene encoding the inflammatory cytokine, and a gene encoding a proteolytic signal sequence to thereby detect an inflammatory reaction induced upon inflammatory stimulation in the transformant or in the transgenic non-human animal.

Abstract: Provided is a pharmaceutical composition for the treatment of disorders such as Niemann-Pick disease and GM1 gangliosidosis which are caused by the storage of cholesterol, such as lysosomal storage disease. Also provided is a method for screening for said pharmaceutical compositions that uses iPS cell strains that phenocopy phentotypes of these disorders. Provided is a pharmaceutical composition for the treatment and/or prevention of lysosomal storage disease, characterized by containing hydroxypropyl-?-cyclodextrin as an active ingredient. Also provided are an iPS cell strain derived from patients suffering from intractable disorders and prepared using a new temperature-sensitive Sendai virus vector, and a screening method for pharmaceuticals using said iPS cell strain.

Abstract: Various embodiments of the present invention are directed to compounds of the formula (I) or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein X1, X2, X3, R1, R2, R11, and n are defined herein. These compounds are useful as inhibitors of HIV-1 protease and, as a result, are useful in the treatment of HIV infection.

Abstract: Provided is a shaft seal device provided with a seal member which possesses excellent liquid tightness, small friction resistance and high wear resistance. In a shaft seal device which is arranged around the periphery of a shaft which is supported in a rotatable manner or in a reciprocating manner, and is provided with a seal member for securing liquid tightness around the shaft, the seal member is formed of a porous body formed by using a hydrophilic polymer resin in which chains are cross-linked. The shaft seal device is also characterized in that: the shaft is a shaft which extends between a liquid phase region and a gas phase region; the seal member is a seal member which suppresses a leakage of a liquid to the gas phase region from the liquid phase region; and an aqueous lubricant which is prepared by adding a water soluble thickening agent is impregnated into the seal member.

Abstract: A purpose of the present invention is to provide a small chemical compound which especially promotes induction of the differentiation of ES cells into insulin-producing cells. Another purpose of the present invention is to provide: a method for inducing the differentiation of ES cells into insulin-producing cells using the compound; and an agent for promoting induction of the differentiation into insulin-producing cells. Another purpose of the present invention is to provide the thus-induced insulin-producing cells. Provided are: an agent for promoting induction of the differentiation of stem cells derived from a mammal into insulin-producing cells, which contains a compound that is selected from the group consisting of dopamine metabolism inhibitors, serotonin metabolism inhibitors, acetylchotine, acetylcholine degrading enzyme inhibitors and acetylcholine receptor activators; and a method for inducing differentiation using the agent for promoting induction of differentiation.

Abstract: There is provided a composite material having excellent adhesion between a resin and a graphene-like carbon material and a method for producing the same. A composite material comprising a substrate comprising a resin, and a graphene-like carbon material layer provided so as to cover at least part of a surface of the substrate, wherein the graphene-like carbon material layer is composed of a graphene-like carbon material obtained by pyrolyzing a polymer in a composition in which the polymer is fixed to graphite or primary exfoliated graphite.

Abstract: Disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof. Specifically disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof, which comprises tranilast as an active ingredient thereof.